Treatment Failure among People living with HIV taking Antiretroviral Therapy in Ethiopia

Background Although treatment failure (TF) among population on antiretroviral therapy (ART) become a major public health threat, its magnitude of and factors leading to it are poorly defined. Hence, we aimed to estimate the magnitude of TF and its determinants in Ethiopia. Methods A follow-up study was conducted from March 2016 to 2017. Clinical and laboratory data were captured from paticipants’ medical record. Socio-demographics and explanatory variables were collected using structured questionnaire. Participants with baseline viral load (VL) >1000 copies/ml were followed for three to six month to clasify virologic failure (VF). Logistic regression was conducted to assess associated risk factors and statistical significance was set at P-value < 0.05. Results A total of 9,284 adults from 63 health facilities were included in the study.Viral load suppression (VLS) were found to be 8,180 (88.1%). Thirty-five percent of the study participants with VL>1000 copies/ml at baseline of the study were re-suppressed after three to six month of adherence counseling and hence VF was found to be 983 (11%). Immunologic and clinical failure was significantly improved from 21.5% and 16.5% at ART initiation to 576 (6.2%) and 470 (5.0%) at baseline of the study, respectively. Adherence, disclosure of HIV status, missed appointment to ART, history of ART exposure prior to initiation, residency and marital status had significant association with VLS. Conclusions VLS (88.1%) could explain the success of ART program in Ethiopia towards the UNAIDS global target. Eleven percent of the population is maintained on a failed first-line regimen. Improving adherence, ensuring disclosure of HIV status and appointment follow-up could improve treatment outcome.

[1]  Dagmar Hartge,et al.  Report , 2019, Datenschutz und Datensicherheit - DuD.

[2]  P. Hill,et al.  Towards achieving the fast-track targets and ending the epidemic of HIV/AIDS in Ethiopia: Successes and challenges. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  Araya Gebreyesus Wasihun,et al.  Virological and immunological failure of HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethiopia , 2018, PloS one.

[4]  M. Ayalew Mortality and Its Predictors among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Systematic Review. , 2017 .

[5]  H. Gesesew,et al.  P3.91 Antiretroviral therapy discontinuation among hiv infected adults in ethiopia in 2003–2015: prevalence, trend and risk factors , 2017, Sexually Transmitted Infections.

[6]  H. Gesesew,et al.  Prevalence, trend and risk factors for antiretroviral therapy discontinuation among HIV-infected adults in Ethiopia in 2003-2015 , 2017, PloS one.

[7]  M. Ayalew,et al.  First-line antiretroviral treatment failure and associated factors in HIV patients at the University of Gondar Teaching Hospital, Gondar, Northwest Ethiopia , 2016, HIV/AIDS.

[8]  G. Shakya,et al.  Virological and Immunological Status of the People Living with HIV/AIDS Undergoing ART Treatment in Nepal , 2016, BioMed research international.

[9]  A. Yalew,et al.  Magnitude and Predictors of Anti-Retroviral Treatment (ART) Failure in Private Health Facilities in Addis Ababa, Ethiopia , 2015, PloS one.

[10]  R. Mash,et al.  HIV and/or AIDS-related deaths and modifiable risk factors: A descriptive study of medical admissions at Oshakati Intermediate Hospital in Northern Namibia. , 2015, African Journal of Primary Health Care & Family Medicine.

[11]  H. Xing,et al.  HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China , 2014, BMJ Open.

[12]  D. Wohl,et al.  Antiretroviral therapy: when to start. , 2014, Infectious disease clinics of North America.

[13]  L. Lynen,et al.  Scaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013 , 2014, Globalization and Health.

[14]  T. F. Rinke de Wit,et al.  HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study , 2014, AIDS Research and Therapy.

[15]  W. Blattner,et al.  Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria , 2013, BMC Infectious Diseases.

[16]  James E. Robinson,et al.  Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis , 2013, BMC Infectious Diseases.

[17]  Gundo Weiler,et al.  Global Update on HIV Treatment 2013: Results, Impact and Opportunities , 2013 .

[18]  T. Quinn,et al.  Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda , 2012, BMC Infectious Diseases.

[19]  M. Arnedo,et al.  Evaluation of Clinical and Immunological Markers for Predicting Virological Failure in a HIV/AIDS Treatment Cohort in Busia, Kenya , 2012, PloS one.

[20]  K. L. Le Roch,et al.  High content live cell imaging for the discovery of new antimalarial marine natural products , 2012, BMC Infectious Diseases.

[21]  Desta Kassa Misgena The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): does success bring further challenges? , 2011 .

[22]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[23]  Ministry OF Health,et al.  The Federal Democratic Republic of Ethiopia , 2020, IMF Staff Country Reports.

[24]  K. Deribe,et al.  Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia , 2008, BMC pediatrics.

[25]  H. Gayle,et al.  HIV/AIDS Prevention and Treatment , 2006 .

[26]  D. Hoover,et al.  Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns , 2005, AIDS.